Understanding early drivers and targets to treat severe ARVD/C
Official title: Understanding Early Drivers and Therapeutic Targets for Severe Forms of Arrhythmogenic Cardiomyopathy
Funded at University of California, San Diego · NIH-11396233 · Data updated 2026-11-12
This study aims to uncover how inflammation and immune responses contribute to a severe form of a genetic heart disease in young people and to identify potential therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 1, 2025 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $699,330 |
| NIH project number | 5R01HL181001-02 |
| Project ID | NIH-11396233 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with DSP-related ARVD/C or related inflammatory cardiac conditions, including pediatric populations, may benefit from future therapies stemming from this work.
✕Less likely to help
Children or adults without ARVD/C or DSP mutations may not benefit from this research.
What this research studies
ARVD/C is a genetic heart disease that can cause sudden death in youths. The project uses mouse models that mimic how inflammation affects DSP-related cardiomyopathy and tests whether blocking certain T cells improves heart health. It also investigates whether DSP-related fragments can act as immune targets in humans. By combining animal data with human tissue insights, the work seeks to pinpoint immune pathways that could be targeted with new treatments. The goal is to lay the groundwork for therapies that could reduce heart damage and improve outcomes for affected patients.
Why it matters
Potential benefit: If successful, the research could guide new treatments that limit heart damage and prevent severe episodes in patients with DSP-related ARVD/C.
How similar studies have gone: Preclinical models have shown that immune cells contribute to heart damage in DSP cardiomyopathy, supporting the potential of immune-targeted therapies.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Sheikh, Farah — University of California, San Diego
- Study coordinator: Sheikh, Farah
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.